1. Home
  2. FCCO vs IKT Comparison

FCCO vs IKT Comparison

Compare FCCO & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Community Corporation

FCCO

First Community Corporation

BUY

Current Price

$32.34

Market Cap

320.5M

Sector

Finance

ML Signal

BUY

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.60

Market Cap

274.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FCCO
IKT
Founded
1994
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
320.5M
274.9M
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
FCCO
IKT
Price
$32.34
$1.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
10
Target Price
★ $37.83
$5.55
AVG Volume (30 Days)
59.9K
★ 559.3K
Earning Date
10-21-2026
11-13-2026
Dividend Yield
★ 2.09%
N/A
EPS Growth
36.46
★ 57.76
EPS
★ 1.39
N/A
Revenue
★ $922,000.00
N/A
Revenue This Year
$27.24
N/A
Revenue Next Year
$7.62
$33.33
P/E Ratio
$23.42
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$25.92
$1.33
52 Week High
$35.74
$2.61

Technical Indicators

Market Signals
Indicator
FCCO
IKT
Relative Strength Index (RSI) 44.05 25.79
Support Level $30.98 $1.59
Resistance Level $33.70 $1.74
Average True Range (ATR) 0.80 0.11
MACD 0.03 -0.03
Stochastic Oscillator 63.68 4.85

Price Performance

Historical Comparison
FCCO
IKT

About FCCO First Community Corporation

First Community Corp is a bank holding company. Along with its subsidiaries, it provides various banking products and services for professionals and small and medium-sized businesses, including consumer and commercial banking, mortgage, brokerage and investment, online banking, and insurance services. The company offers checking, savings, money market, individual retirement, and certificates of deposit accounts, and its lending lines include consumer loans, real estate loans, home improvement loans, home loans, flex loans, construction loans, agricultural loans, and others. The company's reportable segments are: Commercial and Retail Banking, which derives maximum revenue; Mortgage Banking; Investment Advisory and Non-Deposit; and Corporate.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: